OptiBiotix Health (GB:OPTI) has released an update.
OptiBiotix Health reports substantial progress in its 2023 fiscal year with a 41% revenue increase and significant cost reductions. The life sciences company, focused on human microbiome modulation for wellness and disease prevention, has expanded its market presence with new partnerships and increased sales across key products like SlimBiome®. With a strong financial position and continued growth into 2024, OptiBiotix is well-positioned to capitalize on the growing interest in appetite suppression and gut health.
For further insights into GB:OPTI stock, check out TipRanks’ Stock Analysis page.
